CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have advanced gastric, esophageal junction, or pancreatic cancer that has progressed after at least one standard treatment
- Your tumor must have at least 10% of cells with the CLDN18.2 protein (tested by biopsy)
- Be well enough to have an ECOG performance status of 0 or 1 (able to carry out daily activities)
- Not have had prior CAR-T or similar cell therapy
- Not have active infections like hepatitis B or C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
This trial tests a special type of immune therapy called CAR-T, which uses your own blood cells to attack cancer cells that have a specific marker, Claudin 18.2. It may be an option for people with advanced solid tumors (especially pancreatic cancer) that have not responded to other treatments.
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.